Trending NewsTrending NewsNASDAQ:CRBP Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis $3.46 +0.05 (+1.47%) As of 12:54 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Corbus Pharmaceuticals Stock (NASDAQ:CRBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Corbus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.27▼$3.5350-Day Range$2.86▼$11.4652-Week Range$2.81▼$12.88Volume259,361 shsAverage Volume550,245 shsMarket Capitalization$71.31 millionP/E RatioN/ADividend YieldN/APrice Target$35.67Consensus RatingModerate Buy Company Overview Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company based in Norwood, Massachusetts. It develops investigational medicines, with current research focused on cancer and obesity. Its oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, and CRB-601, an antibody targeting the αvβ8 integrin. The company is also developing CRB-913, an investigational drug candidate designed to act on the cannabinoid CB1 receptor for obesity treatment. These candidates are in development and are not approved medicines. Founded in 2014, Corbus previously focused on inflammatory and fibrotic diseases before shifting its research toward oncology and metabolic disorders. The company is led by co-founder and Chief Executive Officer Yuval Cohen.AI Generated. May Contain Errors. Read More Corbus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreCRBP MarketRank™: 3.11861074705 of 5 starsCorbus Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 337th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingCorbus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCorbus Pharmaceuticals has a consensus price target of $35.67, representing about 945.9% upside from its current price of $3.41.Amount of Analyst CoverageCorbus Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Corbus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Corbus Pharmaceuticals are expected to decrease in the coming year, from ($6.33) to ($6.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corbus Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corbus Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorbus Pharmaceuticals has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.01% of the float of Corbus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorbus Pharmaceuticals has a short interest ratio ("days to cover") of 3.48, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Corbus Pharmaceuticals has recently increased by 19.52%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorbus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorbus Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.04 News SentimentCorbus Pharmaceuticals has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Corbus Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for CRBP on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows2 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Corbus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,758,180.00 in company stock.Percentage Held by Insiders3.50% of the stock of Corbus Pharmaceuticals is held by insiders.Percentage Held by Institutions64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corbus Pharmaceuticals' insider trading history. Receive CRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRBP Stock News HeadlinesCorbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Target Lowered at MizuhoNovember 13 at 3:55 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP), Universal Health (UHS) and Legend Biotech (LEGN)November 12 at 11:38 AM | theglobeandmail.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 13 at 1:00 AM | Behind the Markets (Ad)Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate UpdateNovember 10 at 2:10 PM | finance.yahoo.comCorbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate UpdateNovember 10 at 2:10 PM | finance.yahoo.comCorbus Pharmaceuticals: Q3 earnings snapshotNovember 10 at 2:10 PM | msn.comCorbus Pharmaceuticals (CRBP) Set to Release Quarterly Earnings on WednesdayNovember 10 at 1:57 AM | americanbankingnews.comInsider Selling: Corbus Pharmaceuticals (NASDAQ:CRBP) Major Shareholder Sells 425,000 Shares of StockNovember 3, 2026 | insidertrades.comSee More Headlines CRBP Stock Analysis - Frequently Asked Questions How have CRBP shares performed this year? Corbus Pharmaceuticals' stock was trading at $8.14 at the beginning of the year. Since then, CRBP stock has decreased by 58.1% and is now trading at $3.41. How were Corbus Pharmaceuticals' earnings last quarter? Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) posted its quarterly earnings data on Tuesday, November, 10th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by $0.54. When did Corbus Pharmaceuticals IPO? Corbus Pharmaceuticals (CRBP) raised $20 million in an initial public offering on Thursday, April 16th 2015. The company issued 20,206,636 shares at a price of $1.00 per share. Who are Corbus Pharmaceuticals' major shareholders? Top institutional shareholders of Corbus Pharmaceuticals include State Street Corp (1.40%), Doliver Advisors LP (0.41%) and Ieq Capital LLC (0.08%). Insiders that own company stock include Yuval Cohen, Dominic Smethurst, Sean F Moran, Nishant C Saxena, Ian Hodgson, Winston Kung, Yong Ben, Anne Altmeyer and John Kenneth Jenkins. View institutional ownership trends. How do I buy shares of Corbus Pharmaceuticals? Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Corbus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corbus Pharmaceuticals investors own include NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Aurora Cannabis (ACB), Tesla (TSLA), Alibaba Group (BABA) and Cronos Group (CRON). Company Calendar Last Earnings11/10/2026Today11/13/2026Jefferies Global Healthcare Conference11/18/20269th Annual Evercore ISI HealthCONx Conference12/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CRBP's financial health is in the Red zone, according to TradeSmith. CRBP has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CRBP CIK1595097 Webwww.corbuspharma.com Phone(617) 963-0100Fax617-663-6085Employees36Year Founded2009Price Target and Rating Average Price Target for Corbus Pharmaceuticals$35.67 High Price Target$48.00 Low Price Target$23.00 Potential Upside/Downside+922.0%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($6.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$78.54 million Net MarginsN/A Pretax MarginN/A Return on Equity-100.96% Return on Assets-82.70% Debt Debt-to-Equity RatioN/A Current Ratio3.40 Quick Ratio5.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.11 per share Price / Book0.85Miscellaneous Outstanding Shares20,610,000Free Float18,018,000Market Cap$71.93 million OptionableOptionable Beta2.80 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CRBP) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trad...Patriot Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRBP Stock Alerts